Scribe Therapeutics, Sanofi Expand Genetic Medicine Partnership

Article

Collaboration to focus on the treatment and prevention of genomic diseases.

Red blood cells in a hemoglobinopathy, AI Generative. Image Credit: Adobe Stock Images/Катерина Євтехова

Image Credit: Adobe Stock Images/Катерина Євтехова

Scribe Therapeutics, a biotechnology company focusing on the development and engineering of new therapeutics based on CRISPR molecules, has announced an expansion to its partnership with Sanofi. Following the launch of their initial collaboration on editing of natural killer (NK) cell therapies for the treatment of cancer, Sanofi will receive an exclusive license to use Scribe’s CRISPR X-Editing (XE) genome editing technologies for the development of in vivo therapies, including sickle cell disease.

“We are continually impressed by the expertise, rigor, and urgency that Sanofi has brought to our existing ex vivo collaboration, as well as their rapid advancements and innovation in non-viral delivery technologies. Now, we are thrilled to expand our work together into new areas of high unmet need,” said Benjamin Oakes, PhD., co-founder, CEO, Scribe, in a company press release. “This in vivo collaboration further demonstrates the versatility of Scribe’s design-based approaches to CRISPR, which enable greater activity, specificity, and deliverability, ultimately accelerating the development of life-changing therapeutics.”

Reference: Scribe Therapeutics Expands Collaboration with Sanofi to Advance In Vivo Genetic Medicines for Sickle Cell and Other Genomic Diseases. Business Wire. July 17, 2023. Accessed July 20, 2023. https://www.businesswire.com/news/home/20230717825654/en/Scribe-Therapeutics-Expands-Collaboration-with-Sanofi-to-Advance-In-Vivo-Genetic-Medicines-for-Sickle-Cell-and-Other-Genomic-Diseases

Related Videos
Related Content